Dual inhibition of EGFR and AURKA could offer synergistic mechanisms to overcome resistance and suppress tumours such as SCCHN and NSCLC where redundancy in EGFR and AURKA signaling is observed.6–9. This evidence concerns the gene EGFR and non-small cell lung carcinoma.